Skip to main content
Cathay Biotech Inc. logo

Cathay Biotech Inc. — Investor Relations & Filings

Ticker · 688065 ISIN · CNE100004447 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 753 across all filing types
Latest filing 2025-04-21 Management Reports
Country CN China
Listing Shanghai Stock Exchange 688065

About Cathay Biotech Inc.

https://www.cathaybiotech.com/

Cathay Biotech Inc. specializes in the research, development, and commercial-scale production of bio-based materials through synthetic biology and metabolic engineering. The company’s core portfolio features long-chain diacids (LCDA), bio-based pentanediamine, and high-performance bio-based polyamides, including the Terryl and Ecopent product lines. These materials are utilized across various applications such as automotive components, electronics, consumer goods, and specialized textiles. By leveraging biological manufacturing processes to replace traditional thermochemical methods, the company provides sustainable alternatives to petroleum-derived chemicals. Cathay Biotech focuses on delivering high-performance, low-carbon solutions that support the transition toward a circular economy and reduced environmental impact in global supply chains.

Recent filings

Filing Released Lang Actions
2024年度独立董事述职报告（吕发钦）
Management Reports Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2024 from Shanghai Kaisa Biotechnology Co., Ltd. It details the independent director's background, attendance at board and committee meetings, oversight activities, opinions on related party transactions, audit firm appointments, and overall evaluation of governance and compliance during the year. The content focuses on the independent director's duties, governance, and supervisory role rather than financial results or audit opinions alone. It is a formal report by an independent director on their annual duties and observations, which aligns with a Management Reports (MDA) filing type rather than an audit report, annual report, or other categories. The document length is over 5,000 characters and contains substantive content, not just an announcement or certification. Therefore, the best classification is Management Reports (MDA).
2025-04-21 Chinese
2024年度独立董事述职报告（张冰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2024 from Shanghai Kaisa Biotechnology Co., Ltd. It details the independent director's background, attendance at board and committee meetings, oversight activities, opinions on related party transactions, audit firm appointments, and overall evaluation of the company's governance and financial reporting. The content focuses on the independent director's duties and observations rather than presenting financial statements or audit results themselves. The document length is 3750 characters, which is relatively short and consistent with a report or statement rather than a full annual or audit report. It is not a certification or a brief announcement but a detailed narrative report on the independent director's work and opinions. This type of document aligns best with the category of Board/Management Information (MANG), as it relates to governance and management oversight information rather than a full audit report or annual report. Therefore, the classification is MANG with high confidence.
2025-04-21 Chinese
招商证券股份有限公司关于上海凯赛生物技术股份有限公司2024年度募集资金存放与使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from 招商证券股份有限公司 (China Merchants Securities Co., Ltd.) regarding the 2024 annual verification opinion on the deposit and actual use of raised funds by 上海凯赛生物技术股份有限公司 (Shanghai Kaisa Biotechnology Co., Ltd.). It includes extensive financial data on fundraising amounts, usage, management, and compliance with regulatory requirements. The document references regulatory guidelines related to fundraising management and usage, provides tables of funds usage, and includes the sponsor's opinion on compliance. The document is over 10,000 characters, indicating it is a full report rather than a brief announcement. The content focuses specifically on the management and use of raised capital funds, which aligns with the category of Capital/Financing Update (CAP). It is not an annual report (10-K), audit report (AR), or earnings release (ER), nor is it a simple announcement or certification. Therefore, the best fitting classification is Capital/Financing Update (CAP).
2025-04-21 Chinese
2024年非经营性资金占用及其他关联资金往来情况
Regulatory Filings
2025-04-21 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled "上海凯赛生物技术股份有限公司2024 年年度报告" which translates to "Shanghai Cathay Biotech Inc. 2024 Annual Report." It contains detailed sections typical of an annual report, including Chairman's statement, company overview, financial data for the year 2024, management discussion and analysis, corporate governance, environmental and social responsibility, and audited financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial figures, risk disclosures, dividend proposals, and detailed financial metrics for the full fiscal year 2024. There is no indication that this is merely an announcement or a certification letter. Therefore, this document fits the definition of an Annual Report (10-K).
2025-04-21 Chinese
中信证券股份有限公司关于上海凯赛生物技术股份有限公司将部分募投项目节余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of surplus raised funds by Shanghai Kaisa Biotechnology Co., Ltd. It discusses the company's fundraising, investment projects, changes in project implementation, surplus funds, and the decision to permanently supplement working capital with surplus funds. The document references regulatory guidelines and approvals, includes detailed financial figures related to fundraising and project expenditures, and contains the sponsor's verification opinion. It is not an announcement of a report but a formal verification opinion related to fundraising and capital use. This fits the category of Capital/Financing Update (CAP), as it provides an update on the use of raised funds and capital structure changes related to fundraising projects. The document length (5012 characters) and content confirm it is a substantive report rather than a brief announcement or certification. Therefore, the classification is CAP with high confidence.
2025-04-21 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.